## Anuhya Kommalapati

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11409425/publications.pdf

Version: 2024-02-01

933447 996975 16 517 10 15 citations g-index h-index papers 17 17 17 807 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Anti–PD-L1 Treatment Induced Central Diabetes Insipidus. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 365-369.	3.6	88
2	Second-line therapies in advanced biliary tract cancers. Lancet Oncology, The, 2020, 21, e29-e41.	10.7	77
3	Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. Blood, 2018, 131, 265-268.	1.4	73
4	FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. Cancers, 2021, 13, 2968.	3.7	63
5	FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma. Cancer Treatment Reviews, 2019, 78, 1-7.	7.7	57
6	Novel targeted treatment options for advanced cholangiocarcinoma. Expert Opinion on Investigational Drugs, 2018, 27, 709-720.	4.1	42
7	Prevention and treatment of FGFR inhibitor-associated toxicities. Critical Reviews in Oncology/Hematology, 2020, 155, 103091.	4.4	35
8	Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis. Cureus, 2017, 9, e1300.	0.5	29
9	Evaluation and management of skeletal disease in cancer care. Critical Reviews in Oncology/Hematology, 2017, 120, 217-226.	4.4	12
10	Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma. Leukemia and Lymphoma, 2019, 60, 553-555.	1.3	12
11	Potential Role of Metabolic Intervention in the Management of Advanced Differentiated Thyroid Cancer. Frontiers in Oncology, 2017, 7, 160.	2.8	11
12	Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 441-446.	0.4	9
13	Association between facility volume and mortality of patients with classic Hodgkin lymphoma. Cancer, 2020, 126, 757-764.	4.1	5
14	Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents. Translational Cancer Research, 2018, 7, S81-S84.	1.0	3
15	Personalized Medicine in Advanced Cholangiocarcinoma. Oncology & Hematology Review, 2020, 16, 52.	0.2	1
16	Immune Check Point Inhibitors in Cancer Therapy: Beware of "Friendly Fire" Effect., 2017, 3, 5-6.		0